Field Trip Reveals Plans to Help Patients Access Psilocybin and MDMA Through Health Canada Jan 6, 2022
InMed’s Year-End Correspondence To Shareholders Focuses On Its Accomplishments And A Bullish Future Jan 6, 2022
Field Trip Announces Intention to Make Applications on Behalf of Patients to Health Canada’s Special Access Program… Jan 6, 2022
Revive Therapeutics To Expedite Patient Enrollments For Phase 3 COVID Oral Therapeutic Trial Jan 5, 2022
Health Canada’s Special Access Program Will Now Allow Doctors To Request Patient Access To Psychedelics Jan 5, 2022
MariMed Announces Agreement to Acquire Kind Therapeutics USA, LLC, A Maryland Licensed Vertically Integrated Cannabis… Jan 5, 2022
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder to Include Additional Behavioral… Jan 5, 2022
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook Jan 5, 2022
